{ "docId": "019de516-01ce-701d-bd9b-acac15fa9fab", "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88", "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides", "authorId": "oculis", "authorName": "Oculis", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "pageCount": 39, "prevPage": 26, "nextPage": 28, "slideType": "propose_solution", "function": "propose_solution", "density": "overcrowded", "nDataPoints": 3, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/27", "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab", "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json", "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-27", "components": [ { "bbox": { "h": 0.036, "w": 0.109, "x": 0.85, "y": 0.04 }, "kind": "image", "text": "Oculis", "attrs": null, "subkind": "logo", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4a576215-494a-4e18-8a55-beba852ac194", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.239, "x": 0.08, "y": 0.228 }, "kind": "list", "text": "Positive Phase 2 / PoC in DED and Uveitis", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "24adee2f-e2a7-4748-aba4-4181dcb9c033", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.239, "x": 0.36, "y": 0.228 }, "kind": "list", "text": "Advancing into Phase 2b for both indications", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "78ef6ef6-e49d-4fa9-960b-dbdcf40126a1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.239, "x": 0.67, "y": 0.228 }, "kind": "list", "text": "Significant market opportunity", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9f9e6926-4487-486b-b2eb-74a97b0060e8", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.205, "x": 0.69, "y": 0.59 }, "kind": "metric", "text": "~10m patients", "attrs": null, "subkind": "big-number", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "08e9ee81-657d-4b33-857a-a1f0526055fe", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.27, "x": 0.05, "y": 0.38 }, "kind": "paragraph", "text": "DED#1\n85 pts Phase 2 PoC successfully completed", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0310a85a-70e3-4a5b-a644-1a0c47f8c44f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.09, "w": 0.244, "x": 0.355, "y": 0.75 }, "kind": "paragraph", "text": "Advance OCS-02 in Phase 2b as steroid-sparing alternative for chronic and recurring Non-Infectious Anterior Uveitis", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "168296a4-d421-4fa5-a95f-af2ec4b8adc4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.294, "x": 0.655, "y": 0.49 }, "kind": "paragraph", "text": "A unique benefit in DED given its multifactorial nature and heterogenous patient population", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "588e539d-befd-4804-940b-df75da03da17", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.27, "x": 0.05, "y": 0.78 }, "kind": "paragraph", "text": "Uveitis\n32 pts Phase 2 PoC successfully completed", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5a5457b6-406f-4fc1-9720-8886b147ea09", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.244, "x": 0.355, "y": 0.365 }, "kind": "paragraph", "text": "OCS-02 in Phase 2b to evaluate signs in DED (with secondary endpoint in symptoms)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "60da18e9-2ecb-4d6b-b66e-aef7dbc13649", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.01, "w": 0.294, "x": 0.655, "y": 0.63 }, "kind": "paragraph", "text": "Addressable US patient segment for DED", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "99edbe18-bf80-41d0-ada2-121a432b3c51", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.27, "x": 0.05, "y": 0.49 }, "kind": "paragraph", "text": "DED#2\n131 pts Phase 2 PoC successfully completed", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "db088c39-e2f6-4d4d-a425-5fba2b638051", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.244, "x": 0.355, "y": 0.51 }, "kind": "paragraph", "text": "Stratification to validate genetic biomarker in severe DED population", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f3fa0ed4-be14-407d-937f-faec3e75588d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.09, "w": 0.294, "x": 0.655, "y": 0.365 }, "kind": "paragraph", "text": "Potential to become the FIRST precision medicine in Dry Eye Disease – de-risks clinical trial and creates potential market pricing upside", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fb421fa6-c686-43c8-846b-2ab917cbb170", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.01, "w": 0.25, "x": 0.026, "y": 0.95 }, "kind": "source-note", "text": "(1) DED Disease and Landscape - DRG Report, Dec. 2020", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "2dad22ca-931b-4c0e-bf7d-db2db4f2de73", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.949, "x": 0.026, "y": 0.088 }, "kind": "title", "text": "Advancing into Phase 2b for DED & Uveitis with readouts in both indications expected in 2H 2024", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d011154c-e3c3-4e1e-8248-520f02d4f967", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.606, "x": 0.026, "y": 0.047 }, "kind": "title", "text": "OCS-02 | TNFα Inhibitor Biologic Eye Drop", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "741043ce-96ba-4927-9589-ab61f922c65b", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "List presentation", "slug": "list-presentation", "agent": null, "layer": "slide", "matchId": "92708c16-5f89-40ec-9b62-1b80c4da3c64", "evidence": "The slide uses bullet points to present information about the trial, including positive Phase 2 results and next steps.", "confidence": 0.7 } ], "frameworks": [], "arcBeats": [ { "to": 39, "from": 25, "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Impact & Next Steps", "beatSlug": "consultants-gambit-impact-next-steps", "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }